|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
SundayData To Be Presented At MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting Underscore Teva Pharmaceutical Industries Limited (TEVA)s Commitment To Developing Solutions To Meet The Needs Of The MS CommunityJERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that more than 20 company-sponsored abstracts including data on COPAXONE® (glatiramer acetate injection) and laquinimod, an investigational therapy for multiple sclerosis (MS), will be featured at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, September 10 – 13, 2014. “Teva takes pride in its well-established presence in the MS community and on-going efforts to bring convenient, effective therapies to those living with this disease,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries, Ltd. “The data being presented at this year’s joint ACTRIMS-ECTRIMS meeting continues to demonstrate our commitment to researching and developing new treatment options to benefit and meet the needs of this diverse patient population.” Story Source: The above story is based on materials provided by BIOSPACE Note: Materials may be edited for content and length Click here to read original article |